کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
3408611 | 1223672 | 2006 | 5 صفحه PDF | دانلود رایگان |

The aim of this study was to evaluate the performance of two antibody enzyme-linked immunosorbent assays (ELISAs) [Vironostika Uni-Form II plus O and Enzygnost® anti-HIV-1/2 Plus], and two antigen/antibody combination ELISAs [Murex and Vironostika HIV Uni-Form II] for use in an alternative confirmatory HIV diagnostic testing strategy in Dar es Salaam, Tanzania. Altogether, 1380 serum samples were included. All ELISA reactive samples were tested using the Inno-Lia antibody assay and discrepant samples were tested on the Innotest p24 antigen assay. Three hundred and one (21.8%) samples were confirmed HIV-1 antibody positive by Inno-Lia including 27/508 (5.3%) from blood donors, 65/511 (12.7%) from pregnant women and 209/361 (57.9%) from hospital patients. The sensitivity at initial testing was 100% (95% CI; 98.8–100%) for all assays except Vironostika Uni-Form II plus O (99.7%; 95% CI; 98.2–99.9%) which showed one false negative sample at initial testing but 100% sensitivity after repeat testing. The final specificity at repeat testing was 100% (95% CI; 99.7–100%) for Enzygnost® anti-HIV-1/2 Plus, 99.4% (95% CI; 98.8–99.8%) for each of the antigen/antibody combination ELISAs and 97.9% (95% CI; 96.8–98.6%) for Vironostika plus O ELISA. An alternative confirmatory HIV testing strategy based on initial testing on any of the two antigen/antibody assays followed by testing of reactive samples on the Enzygnost® anti-HIV-1/2 Plus assay gave 100% specificity (95% CI; 99.7–100%).
Journal: Journal of Virological Methods - Volume 135, Issue 2, August 2006, Pages 192–196